热门资讯> 正文

Immunovant GAAP每股收益为-0.71美元

2025-08-11 19:21

Immunovant press release (NASDAQ:IMVT): Q1 GAAP EPS of -$0.71 misses by $0.02.
As of June 30, 2025, Immunovant’s cash and cash equivalents totaled approximately $598.9 million, providing runway for announced indications through GD readout expected in 2027.

More on Immunovant

Immunovant: Navigating The Complexities Of The FcRn Landscape (Downgrade)
Seeking Alpha’s Quant Rating on Immunovant
Historical earnings data for Immunovant
Financial information for Immunovant

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。